{ "run": { "id": "cmnr135t302yzp6580nklfywa", "region": "US", "assetId": "cmnr134vr02ykp658x4li2n7b", "ticker": "COR", "snapshotId": "cmnr135sl02yop6588zjljsra", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:17.701Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr135sl02yop6588zjljsra", "assetId": "cmnr134vr02ykp658x4li2n7b", "asOf": "2026-04-08T20:00:03.000Z", "snapshot": { "asOf": "2026-04-08T20:00:03.000Z", "quote": { "asOf": "2026-04-08T20:00:03.000Z", "open": null, "price": 324.93, "dayLow": 315.09, "volume": 674981, "dayHigh": 325.14, "currency": "USD", "prevClose": 320.89, "week52Low": 269.37, "week52High": 377.54 }, "fundamentals": { "pe": 38.9688279301746, "beta": 0.316418692614682, "epsTTM": 8.02, "fcfTTM": 2950348000, "growth": { "epsYoy": 0.05526315789473683, "revenueYoy": -0.7325762856485568 }, "sector": "Wholesale-Drugs, Proprietaries & Druggists' Sundries", "margins": { "net": 0.006512671598441261, "gross": 0.03575001661778772, "operating": 0.008849425806558524 }, "website": "https://cencora.com/", "industry": "Pharmaceutical industry", "pegRatio": 7.05150219688872, "ebitdaTTM": 2692475000, "forwardPe": 17.7372304199773, "marketCap": 37887695618, "totalCash": 1753122000, "totalDebt": 8264011000, "debtEquity": 5.15812997051098, "quickRatio": 0.4690011636480798, "revenueTTM": 85932016000, "companyName": "Cencora, Inc.", "priceToBook": 0.79808402331152, "currentRatio": 0.9157723179944497, "dividendYield": 0.00721558632548553, "returnOnAssets": 0.007141887822207552, "returnOnEquity": 1.03060306269351, "analystOpinions": null, "businessSummary": "Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment.", "enterpriseValue": 63996984600, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 51000, "sharesOutstanding": 194530682, "enterpriseToEbitda": 23.76883150261376, "analystTargetMedian": null, "enterpriseToRevenue": 0.7447397091207543, "operatingCashflowTTM": -2305169000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:17.686Z" }, "results": [ { "id": "cmnr135t602z1p658zbv6mj67", "runId": "cmnr135t302yzp6580nklfywa", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"COR\",\"currency\":\"USD\",\"current_price\":324.93,\"target_price_6m\":333,\"target_price_12m\":342,\"recommendation\":\"HOLD\",\"confidence\":0.6,\"thesis_bullets\":[\"Pharmaceutical distribution is defensive but low-margin and fairly valued\",\"Forward PE ~17.7x is reasonable for stable distributor, limited re-rating catalyst\",\"Strong FCF generation (~$2.95B TTM) supports dividends and buybacks\",\"High leverage (D/E 5.16x) constrains financial flexibility in rising rate environment\",\"Revenue decline likely reflects accounting reclassification, not organic deterioration\"],\"key_drivers\":[{\"driver\":\"Pharmaceutical volume growth and drug price inflation\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Specialty pharma and biosimilar distribution expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Share buyback program supporting EPS growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"High financial leverage limiting strategic flexibility\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Thin operating margins (~0.9%) vulnerable to cost pressures\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"GLP-1 and specialty drug distribution tailwinds\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Potential opioid litigation settlement liabilities\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Negative operating cash flow timing normalization\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Elevated debt-to-equity (5.16x) creates refinancing risk if rates stay elevated\",\"Opioid litigation exposure could result in material settlements\",\"Customer concentration risk with large pharmacy chains\",\"Margin compression from generic drug deflation or competitive pricing\",\"Regulatory changes in drug pricing could reduce distribution economics\",\"Working capital volatility as shown by negative operating cash flow\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.012,\"wacc\":0.085,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":280,\"prob\":0.2,\"notes\":\"Multiple compresses to 15x forward on margin pressure or litigation overhang.\"},\"base\":{\"target_price\":342,\"prob\":0.55,\"notes\":\"Steady EPS growth with stable ~18x forward multiple and continued buybacks.\"},\"bull\":{\"target_price\":380,\"prob\":0.25,\"notes\":\"Specialty pharma tailwinds and margin expansion drive re-rating to ~20x forward.\"}},\"method_notes\":\"Valued on forward PE (snapshot forward PE ~17.7x implying ~$18.3 fwd EPS). Applied 18x base multiple consistent with pharma distributor peers (MCK, CAH). 12M base target assumes ~5% EPS growth to ~$19 × 18x = ~$342. Expected return ~5.2% is within HOLD range given mixed signals: strong FCF offset by high leverage, thin margins, and fair valuation. Revenue YoY decline (-73%) appears to be a reporting reclassification, not organic. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "ai-equity-research-v1", "risks": [ "Elevated debt-to-equity (5.16x) creates refinancing risk if rates stay elevated", "Opioid litigation exposure could result in material settlements", "Customer concentration risk with large pharmacy chains", "Margin compression from generic drug deflation or competitive pricing", "Regulatory changes in drug pricing could reduce distribution economics", "Working capital volatility as shown by negative operating cash flow" ], "ticker": "COR", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady EPS growth with stable ~18x forward multiple and continued buybacks.", "target_price": 342 }, "bear": { "prob": 0.2, "notes": "Multiple compresses to 15x forward on margin pressure or litigation overhang.", "target_price": 280 }, "bull": { "prob": 0.25, "notes": "Specialty pharma tailwinds and margin expansion drive re-rating to ~20x forward.", "target_price": 380 } }, "confidence": 0.6, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.012 }, "key_drivers": [ { "driver": "Pharmaceutical volume growth and drug price inflation", "impact": "HIGH", "direction": "POS" }, { "driver": "Specialty pharma and biosimilar distribution expansion", "impact": "MED", "direction": "POS" }, { "driver": "Share buyback program supporting EPS growth", "impact": "MED", "direction": "POS" }, { "driver": "High financial leverage limiting strategic flexibility", "impact": "HIGH", "direction": "NEG" }, { "driver": "Thin operating margins (~0.9%) vulnerable to cost pressures", "impact": "MED", "direction": "NEG" }, { "driver": "GLP-1 and specialty drug distribution tailwinds", "impact": "MED", "direction": "POS" }, { "driver": "Potential opioid litigation settlement liabilities", "impact": "MED", "direction": "NEG" }, { "driver": "Negative operating cash flow timing normalization", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valued on forward PE (snapshot forward PE ~17.7x implying ~$18.3 fwd EPS). Applied 18x base multiple consistent with pharma distributor peers (MCK, CAH). 12M base target assumes ~5% EPS growth to ~$19 × 18x = ~$342. Expected return ~5.2% is within HOLD range given mixed signals: strong FCF offset by high leverage, thin margins, and fair valuation. Revenue YoY decline (-73%) appears to be a reporting reclassification, not organic. Not investment advice.", "current_price": 324.93, "recommendation": "HOLD", "thesis_bullets": [ "Pharmaceutical distribution is defensive but low-margin and fairly valued", "Forward PE ~17.7x is reasonable for stable distributor, limited re-rating catalyst", "Strong FCF generation (~$2.95B TTM) supports dividends and buybacks", "High leverage (D/E 5.16x) constrains financial flexibility in rising rate environment", "Revenue decline likely reflects accounting reclassification, not organic deterioration" ], "target_price_6m": 333, "target_price_12m": 342 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 41328, "createdAt": "2026-04-09T05:20:17.701Z", "usage": { "inputTokens": 3637, "outputTokens": 1784, "costUsd": 0.062785 } }, { "id": "cmnr135t602z4p6581j1il142", "runId": "cmnr135t302yzp6580nklfywa", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity_Research_Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"COR\",\n \"currency\": \"USD\",\n \"current_price\": 324.93,\n \"target_price_6m\": 330.0,\n \"target_price_12m\": 340.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Leading pharmaceutical distributor with stable demand.\",\n \"Recent restructuring may boost efficiency and margins.\",\n \"High debt levels increase financial risk and volatility.\",\n \"Thin margins with potential for slight improvement.\",\n \"Valuation appears fair based on forward earnings metrics.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Pharmaceutical industry growth\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Cost control and efficiency initiatives\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt reduction and financial restructuring\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory changes in drug distribution\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competitive pressure in wholesale sector\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Earnings recovery post-name change\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Interest rate environment affecting debt costs\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"High leverage and debt burden increasing bankruptcy risk\",\n \"Margin compression from intense pricing competition\",\n \"Regulatory hurdles and compliance costs\",\n \"Economic downturn reducing healthcare spending\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.01,\n \"ebit_margin_target\": 0.015,\n \"wacc\": 0.08,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 300.0, \"prob\": 0.3, \"notes\": \"Margins worsen and debt issues escalate, leading to downside.\" },\n \"base\": { \"target_price\": 340.0, \"prob\": 0.5, \"notes\": \"Moderate improvement in earnings and financial stability.\" },\n \"bull\": { \"target_price\": 380.0, \"prob\": 0.2, \"notes\": \"Successful restructuring boosts margins and growth.\" }\n },\n \"method_notes\": \"Valuation based on forward earnings and EV/EBITDA multiples, with mixed evidence. HOLD due to limited upside and balanced risks. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "Equity_Research_Model", "risks": [ "High leverage and debt burden increasing bankruptcy risk", "Margin compression from intense pricing competition", "Regulatory hurdles and compliance costs", "Economic downturn reducing healthcare spending" ], "ticker": "COR", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate improvement in earnings and financial stability.", "target_price": 340 }, "bear": { "prob": 0.3, "notes": "Margins worsen and debt issues escalate, leading to downside.", "target_price": 300 }, "bull": { "prob": 0.2, "notes": "Successful restructuring boosts margins and growth.", "target_price": 380 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.01, "terminal_multiple": 15, "ebit_margin_target": 0.015 }, "key_drivers": [ { "driver": "Pharmaceutical industry growth", "impact": "MED", "direction": "POS" }, { "driver": "Cost control and efficiency initiatives", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction and financial restructuring", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory changes in drug distribution", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive pressure in wholesale sector", "impact": "HIGH", "direction": "NEG" }, { "driver": "Earnings recovery post-name change", "impact": "HIGH", "direction": "POS" }, { "driver": "Interest rate environment affecting debt costs", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on forward earnings and EV/EBITDA multiples, with mixed evidence. HOLD due to limited upside and balanced risks. not investment advice.", "current_price": 324.93, "recommendation": "HOLD", "thesis_bullets": [ "Leading pharmaceutical distributor with stable demand.", "Recent restructuring may boost efficiency and margins.", "High debt levels increase financial risk and volatility.", "Thin margins with potential for slight improvement.", "Valuation appears fair based on forward earnings metrics." ], "target_price_6m": 330, "target_price_12m": 340 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 336, "createdAt": "2026-04-09T05:20:17.701Z", "usage": { "inputTokens": 2148, "outputTokens": 3982, "costUsd": 0.002274 } }, { "id": "cmnr135t602z2p658lshg5siz", "runId": "cmnr135t302yzp6580nklfywa", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_Cencora_v1\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"COR\",\n \"currency\": \"USD\",\n \"current_price\": 324.93,\n \"target_price_6m\": 332.00,\n \"target_price_12m\": 340.00,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Oligopoly position in drug distribution ensures highly stable, recurring cash flow generation.\",\n \"Forward P/E of 17.7x appears fully valued compared to historical sector averages.\",\n \"Strong free cash flow of $2.95B supports consistent share repurchases and dividend growth.\",\n \"Specialty pharmaceuticals and biosimilars provide a solid runway for margin expansion.\",\n \"Defensive beta offers downside protection, but near-term upside is limited by valuation.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Specialty drug volumes\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Generic drug pricing trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Share repurchase program\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"GLP-1 distribution margins\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Biosimilar adoption rates\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory scrutiny on distributors\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Interest expense reduction\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Deflationary pricing in generic pharmaceuticals compressing already thin operating margins.\",\n \"Regulatory changes to drug pricing or distribution reimbursement models.\",\n \"Customer consolidation leading to increased pricing pressure and lower contract profitability.\",\n \"Slower than expected uptake of high-margin biosimilars in the US market.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.012,\n \"wacc\": 0.075,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 280.00,\n \"prob\": 0.25,\n \"notes\": \"Multiple compression to 14x forward earnings due to generic pricing pressure and GLP-1 slowdown.\"\n },\n \"base\": {\n \"target_price\": 340.00,\n \"prob\": 0.55,\n \"notes\": \"Steady mid-single-digit EPS growth with the multiple holding near 16x-17x.\"\n },\n \"bull\": {\n \"target_price\": 390.00,\n \"prob\": 0.2,\n \"notes\": \"Stronger specialty drug utilization and accretive capital deployment push multiple to 19x.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of 15x terminal P/E and DCF (7.5% WACC). At 17.7x forward P/E, COR is fairly valued. HOLD recommendation reflects ~4.6% upside to our 12M target. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "EquityResearch_Cencora_v1", "risks": [ "Deflationary pricing in generic pharmaceuticals compressing already thin operating margins.", "Regulatory changes to drug pricing or distribution reimbursement models.", "Customer consolidation leading to increased pricing pressure and lower contract profitability.", "Slower than expected uptake of high-margin biosimilars in the US market." ], "ticker": "COR", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady mid-single-digit EPS growth with the multiple holding near 16x-17x.", "target_price": 340 }, "bear": { "prob": 0.25, "notes": "Multiple compression to 14x forward earnings due to generic pricing pressure and GLP-1 slowdown.", "target_price": 280 }, "bull": { "prob": 0.2, "notes": "Stronger specialty drug utilization and accretive capital deployment push multiple to 19x.", "target_price": 390 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.06, "terminal_multiple": 15, "ebit_margin_target": 0.012 }, "key_drivers": [ { "driver": "Specialty drug volumes", "impact": "HIGH", "direction": "POS" }, { "driver": "Generic drug pricing trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Share repurchase program", "impact": "MED", "direction": "POS" }, { "driver": "GLP-1 distribution margins", "impact": "MED", "direction": "POS" }, { "driver": "Biosimilar adoption rates", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory scrutiny on distributors", "impact": "MED", "direction": "NEG" }, { "driver": "Interest expense reduction", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a blend of 15x terminal P/E and DCF (7.5% WACC). At 17.7x forward P/E, COR is fairly valued. HOLD recommendation reflects ~4.6% upside to our 12M target. Not investment advice.", "current_price": 324.93, "recommendation": "HOLD", "thesis_bullets": [ "Oligopoly position in drug distribution ensures highly stable, recurring cash flow generation.", "Forward P/E of 17.7x appears fully valued compared to historical sector averages.", "Strong free cash flow of $2.95B supports consistent share repurchases and dividend growth.", "Specialty pharmaceuticals and biosimilars provide a solid runway for margin expansion.", "Defensive beta offers downside protection, but near-term upside is limited by valuation." ], "target_price_6m": 332, "target_price_12m": 340 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 24052, "createdAt": "2026-04-09T05:20:17.701Z", "usage": { "inputTokens": 2515, "outputTokens": 904, "costUsd": 0.015878 } }, { "id": "cmnr135t602z0p658lp4wngb7", "runId": "cmnr135t302yzp6580nklfywa", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"COR\",\"currency\":\"USD\",\"current_price\":324.93,\"target_price_6m\":336,\"target_price_12m\":341,\"recommendation\":\"HOLD\",\"confidence\":0.61,\"thesis_bullets\":[\"Defensive pharma distribution with scale and sticky manufacturer/provider relationships.\",\"Specialty and oncology mix supports steadier growth than core drug wholesaling.\",\"Forward earnings multiple looks full for modest margin, low-growth distribution economics.\",\"Strong FCF and buybacks offset thin margins and leverage concerns.\",\"Mixed setup: resilient demand, but limited multiple expansion from current levels.\"],\"key_drivers\":[{\"driver\":\"Specialty distribution growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Core drug volume resilience\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Manufacturer services expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Share repurchases\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Low operating margins\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Reimbursement pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Generic pricing normalization\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Valuation already rich\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Contract renewals or customer concentration pressure\",\"Generic sourcing and pricing swings\",\"Litigation or regulatory costs\",\"Working-capital volatility distorting cash flow\",\"Margin compression from mix or reimbursement\"],\"assumptions\":{\"revenue_cagr_3y\":6,\"ebit_margin_target\":1,\"wacc\":7.5,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":285,\"prob\":0.25,\"notes\":\"Multiple compresses as growth normalizes and margins stay pinned near current levels.\"},\"base\":{\"target_price\":341,\"prob\":0.5,\"notes\":\"Defensive demand, modest EPS growth, and limited multiple expansion support mid-single-digit upside.\"},\"bull\":{\"target_price\":390,\"prob\":0.25,\"notes\":\"Specialty growth and buybacks drive faster EPS compounding with valuation holding firm.\"}},\"method_notes\":\"Targets use snapshot quote/fundamentals plus a normalized 12M forward P/E and FCF cross-check for a defensive distributor. Snapshot growth/cash-flow fields show anomalies, so I leaned on normalized margins and forward PE rather than raw TTM trends. No sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Model Recommendation v2", "risks": [ "Contract renewals or customer concentration pressure", "Generic sourcing and pricing swings", "Litigation or regulatory costs", "Working-capital volatility distorting cash flow", "Margin compression from mix or reimbursement" ], "ticker": "COR", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Defensive demand, modest EPS growth, and limited multiple expansion support mid-single-digit upside.", "target_price": 341 }, "bear": { "prob": 0.25, "notes": "Multiple compresses as growth normalizes and margins stay pinned near current levels.", "target_price": 285 }, "bull": { "prob": 0.25, "notes": "Specialty growth and buybacks drive faster EPS compounding with valuation holding firm.", "target_price": 390 } }, "confidence": 0.61, "assumptions": { "wacc": 7.5, "revenue_cagr_3y": 6, "terminal_multiple": 18, "ebit_margin_target": 1 }, "key_drivers": [ { "driver": "Specialty distribution growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Core drug volume resilience", "impact": "MED", "direction": "POS" }, { "driver": "Manufacturer services expansion", "impact": "MED", "direction": "POS" }, { "driver": "Share repurchases", "impact": "HIGH", "direction": "POS" }, { "driver": "Low operating margins", "impact": "HIGH", "direction": "NEG" }, { "driver": "Reimbursement pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Generic pricing normalization", "impact": "MED", "direction": "NEG" }, { "driver": "Valuation already rich", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Targets use snapshot quote/fundamentals plus a normalized 12M forward P/E and FCF cross-check for a defensive distributor. Snapshot growth/cash-flow fields show anomalies, so I leaned on normalized margins and forward PE rather than raw TTM trends. No sell-side targets used; not investment advice.", "current_price": 324.93, "recommendation": "HOLD", "thesis_bullets": [ "Defensive pharma distribution with scale and sticky manufacturer/provider relationships.", "Specialty and oncology mix supports steadier growth than core drug wholesaling.", "Forward earnings multiple looks full for modest margin, low-growth distribution economics.", "Strong FCF and buybacks offset thin margins and leverage concerns.", "Mixed setup: resilient demand, but limited multiple expansion from current levels." ], "target_price_6m": 336, "target_price_12m": 341 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_07bbd6754979e4270069d757951ca88194a8388ea07be6c60b", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 30832, "createdAt": "2026-04-09T05:20:17.701Z", "usage": { "inputTokens": 2415, "outputTokens": 1728, "costUsd": 0.028418 } }, { "id": "cmnr135t602z3p6585q4z0gjm", "runId": "cmnr135t302yzp6580nklfywa", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Fundamental DCF Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"COR\",\n \"currency\": \"USD\",\n \"current_price\": 324.93,\n \"target_price_6m\": 345,\n \"target_price_12m\": 375,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Dominant position in US drug distribution oligopoly.\",\n \"Growing specialty drugs segment improves profitability.\",\n \"Robust cash flow funds dividends and buybacks.\",\n \"Attractive forward PE versus historical averages.\",\n \"Elevated debt and thin margins pose risks.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Oligopoly market structure\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Specialty pharma growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Healthcare spending trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Margin expansion potential\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"High debt burden\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory compliance costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Supply chain efficiencies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Peer competition intensity\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Persistent revenue contraction\",\n \"Opioid litigation exposure\",\n \"Drug pricing regulation\",\n \"Interest rate pressure on debt\",\n \"Supply chain disruptions\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 4.5,\n \"ebit_margin_target\": 1.1,\n \"wacc\": 7.5,\n \"terminal_multiple\": 16\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 280,\n \"prob\": 0.25,\n \"notes\": \"Revenue decline persists and margins contract.\"\n },\n \"base\": {\n \"target_price\": 375,\n \"prob\": 0.5,\n \"notes\": \"Steady growth and stable margins achieved.\"\n },\n \"bull\": {\n \"target_price\": 440,\n \"prob\": 0.25,\n \"notes\": \"Accelerated specialty growth and margin gains.\"\n }\n },\n \"method_notes\": \"DCF using revenue CAGR, EBIT margin, WACC and terminal multiple; 15% 12M upside supports BUY. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "Fundamental DCF Model", "risks": [ "Persistent revenue contraction", "Opioid litigation exposure", "Drug pricing regulation", "Interest rate pressure on debt", "Supply chain disruptions" ], "ticker": "COR", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady growth and stable margins achieved.", "target_price": 375 }, "bear": { "prob": 0.25, "notes": "Revenue decline persists and margins contract.", "target_price": 280 }, "bull": { "prob": 0.25, "notes": "Accelerated specialty growth and margin gains.", "target_price": 440 } }, "confidence": 0.62, "assumptions": { "wacc": 7.5, "revenue_cagr_3y": 4.5, "terminal_multiple": 16, "ebit_margin_target": 1.1 }, "key_drivers": [ { "driver": "Oligopoly market structure", "impact": "HIGH", "direction": "POS" }, { "driver": "Specialty pharma growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Healthcare spending trends", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin expansion potential", "impact": "MED", "direction": "POS" }, { "driver": "High debt burden", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory compliance costs", "impact": "MED", "direction": "NEG" }, { "driver": "Supply chain efficiencies", "impact": "MED", "direction": "POS" }, { "driver": "Peer competition intensity", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using revenue CAGR, EBIT margin, WACC and terminal multiple; 15% 12M upside supports BUY. not investment advice.", "current_price": 324.93, "recommendation": "BUY", "thesis_bullets": [ "Dominant position in US drug distribution oligopoly.", "Growing specialty drugs segment improves profitability.", "Robust cash flow funds dividends and buybacks.", "Attractive forward PE versus historical averages.", "Elevated debt and thin margins pose risks." ], "target_price_6m": 345, "target_price_12m": 375 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "54eea961-fedc-9fd1-b9a6-468be4d3a472", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 12283, "createdAt": "2026-04-09T05:20:17.701Z", "usage": { "inputTokens": 2756, "outputTokens": 2581, "costUsd": 0.046983 } } ] } }